Post by
BowenQueen on Dec 11, 2020 3:20pm
Why Algernon could have the leading therapeutic COVID19 drug
Today, BNN Bloomberg published an article highlighting Algernon Pharmaceuticals' hard work repurposing Ifenprodil for those affected by idiopathic pulmonary fibrosis, chronic cough, as well as COVID-19. The company investigates approved drugs with established safety histories for new disease applications, moving them efficiently and safely into new human trials, developing new formulations, and seeking new regulatory approvals in global markets.
"Developing a new drug from scratch catered towards fighting off COVID-19 could take years. Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues and can therefore go through the approval pipeline quicker. For instance, a drug repurposing strategy can save up to eight years of pre-clinical research and millions in R&D costs. Since Algernon’s value proposition is centered around repurposing previously approved compounds, this makes the company an intriguing investment opportunity."
Read the full article on BNN Bloomberg: https://www.bnnbloomberg.ca/why-algernon-pharmaceuticals-could-have-the-leading-therapeutic-drug-for-the-covid-19-pandemic-1.1534525
Learn more about Algernon Pharmaceuticals: https://algernonpharmaceuticals.com/
Comment by
Biofinanace on Dec 11, 2020 3:37pm
Very pleased to see AGN's coverage on BNN Thanks for sharing